4 minute read
Dec. 28, 2022

Ervogastat: A First-in-Class DGAT2 Inhibitor for NASH?


systemic, oral DGAT2 inhibitor Ph. II for NASH with fibrosis opt. of liver-targeting candidate PF-06427878 J. Med. Chem., 02 November 2022 Pfizer, Cambridge, MA and Groton, CT

Drug Hunter Team

Toward a first-in-class DGAT2 inhibitor for the treatment of NASH. Hepatic triglyceride (TG) accumulation is a symptom of non-alcoholic fatty liver disease ( NAFLD ), which can progress to non-alcoholic steatohepatitis ( NASH ), which is characterized by hepatocyte damage, inflammation and collagen deposits (fibrosis). NASH has been estimated [...]



Other molecules you may be interested in